Coherus BioSciences ( NASDAQ:CHRS ) First Quarter 2024 Results Key Financial Results Revenue: US$77.1m (up 138% from 1Q...
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript May 10, 2024. CHRS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to Coherus […]
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -540% and 24.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?